Due to recent evidence of IL-6 inducing the CSC subpopulation and mediating therapeutic resistance in breast cancer, preclinical investigations in metastatic breast cancer focus on targeting this pathway with either mAbs, novel small molecule compounds, or by repurposing current FDA-approved compounds. Here, IL6 is linked to breast cancer.